<DOC>
	<DOCNO>NCT00685646</DOCNO>
	<brief_summary>RATIONALE : Androgens cause growth prostate cancer cell . Androgen blockade therapy may lessen amount androgen make body . Zoledronic acid may help relieve symptom cause bone metastasis . It yet know whether androgen-blockade therapy effective without zoledronic acid treat patient prostate cancer spread bone . PURPOSE : This randomized phase III trial study androgen-blockade therapy give together zoledronic acid see well work compare androgen-blockade therapy alone treat patient prostate cancer bone metastasis .</brief_summary>
	<brief_title>Androgen Blockade Therapy With Without Zoledronic Acid Treating Patients With Prostate Cancer Bone Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate time treatment failure prostatic cancer patient metastatic bone disease receive maximum androgen-blockade therapy v without zoledronic acid . - Evaluate time first skeletal-related event patient . - Evaluate overall survival patient . - Evaluate extent disease bone scan patient . - Evaluate pain scale FACES pain-rating scale patient . - Evaluate safety regimens patient . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive maximum androgen-blockade therapy zoledronic acid 24 course absence disease progression unacceptable toxicity . - Arm II : Patients receive maximum androgen-blockade therapy 24 course absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Patients definitive diagnosis prostatic cancer histopathological diagnosis cytology Androgen blockade therapy , systemic chemotherapy , bisphosphonatesnaïve prostatic cancer patient Patients sensitive androgen blockade therapy Patients bone metastasis bone scan ( EOD ≥ 1 ) Patients Eastern Cooperative Oncology Group performance status ( ECOG : 02 ) Patients prostatespecific antigen performance status ( PSA ≧30 ng/mL ) Patients demonstrate appropriate bone marrow , hepatic renal function laboratory test within four week registration . Leukocyte count ≥ 3,000/μL Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 7.5 × 10^4/μL Serum creatine level ≤ 3.0 mg/dL 8.5 mg/dL ≤ correct serum level calcium ≤ 11.5 mg/dL Total bilirubin ≤ 1.8 mg/dL Aspartate aminotransferase ( AST ) Levels ≤ 90 IU/L Alanine aminotransferase ( ALT ) Levels ≤ 100 IU/L Patients agree participate clinical study write receive sufficient explanation Exclusion criterion : Patients poorlycontrolled dental caries Patients double cancer require treatment Patients use follow steroid drug ( except topical ointment ) Patients poorlycontrolled hypertension cardiovascular disease Patients active infectious disease HIV hepatitis virus infection Other patient whose participation present study consider inappropriate Principal Investigator Clinical Investigator PRIOR CONCURRENT THERAPY : No prior androgenblockade therapy No prior concurrent anticancer therapy No prior concurrent immunologic adjuvant therapy No prior concurrent steroid drug ( except ointment ) No prior concurrent bisphosphonates ( exclude zoledronic acid ) No prior systemic chemotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>bone metastasis</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>